Febuxostat + Tigulixostat
Phase 3Recruiting 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedAbout Febuxostat + Tigulixostat
Febuxostat + Tigulixostat is a phase 3 stage product being developed by Innovent Biologics for Gout. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07414394. Target conditions include Gout.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07414394 | Phase 3 | Recruiting |
Competing Products
20 competing products in Gout